Visfatin is an adipocytokine with important roles in endothelial angiogenesis.
| INTRODUC TI ON
Visceral fat accumulation has been shown to play important roles in the development of cardiovascular diseases. 1, 2 Fat tissue is an endocrine organ producing adipocytokines that influence energy and lipid metabolism, insulin sensitivity, blood pressure, inflammation and angiogenesis. 1 The well-known adipocytokine, visfatin, was initially demonstrated to improve insulin sensitivity. 3 Further researches 4, 5 showed that visfatin expression increased by hypoxia, enhancing angiogenesis in adipocytes and breast cancer cells through hypoxia-inducible factor-1α (HIF-1α). Visfatin was also shown to be associated with the expression of fibroblast growth factor 2 (FEF-2), signal transducer and activator of transcription 3 (STAT3), vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP) and monocyte-chemoattractant protein-1 (MCP-1), all of which enhance angiogenesis. [6] [7] [8] [9] [10] Angiogenesis is activated by visfatin in endothelial cells (ECs) through HIF-1α by increased cell migration and tube formation. [6] [7] [8] [10] [11] [12] [13] Under hypoxia, ECs stimulate angiogenesis by expression of cardiac-restricted genes through various signalling cascades. [14] [15] [16] [17] [18] Models in vascular smooth muscle cells (VSMCs) and cardiomyocytes revealed that visfatin reduced cell death following exposure to hypoxia. 19, 20 Hypoxia also stimulates pro-inflammatory cytokines, such as angiotensin II (AngII), to mediate visfatin-induced angiogenesis. 4, 5 AngII has been shown to induce visfatin expression in ECs and cardiomyocytes. 21, 22 However, the effect of hypoxia on visfatin-mediated angiogenesis is not yet fully understood in human coronary artery ECs (HCAECs). Hyperbaric oxygen (HBO) therapy provides an increase in oxygen supply in hypo-perfused tissues 23 and enhances wound healing by increasing fibroblastic replication, collagen synthesis and neovascularization.. [24] [25] [26] However, the effect of HBO on visfatin in hypoxic HCAECs to enhance angiogenesis has not been explored.
Our previous study showed that HBO-induced visfatin expression in HCAECs is mediated by tumour necrosis factor-α (TNF-α) through the c-Jun N-terminal kinase (JNK) pathway. 27 Thus, visfatin and the JNK pathway may be key mediators of angiogenesis in HCAECs under HBO. The aim of this study was to investigate the molecular mechanisms mediating visfatin expression by HBO in hypoxic HCAECs. We have been suggested that HIF-1α may play a role in the transcriptional regulation of visfatin in hypoxic HCAECs treated with HBO.
| MATERIAL AND ME THODS

| Primary HCAEC culture
HCAECs were purchased from PromoCell GmbH company and were then cultured in EC growth medium supplemented with foetal bovine serum (FBS, 10%), penicillin (100 U/mL) and streptomycin (100 µg/ mL) at 37°C in a humidified atmosphere with 5% CO 2 . HCAECs were grown up to 90% in confluency in 10-cm 2 culture dishes and were then sub-cultured at a ratio of 1:2.
| Chemical hypoxia
Chemical hypoxia was generated by using 0.01 mmol/L antimycin A from Sigma-Aldrich with glucose-free medium (Dulbecco's Modified Eagle Medium; DMEM) as described previously. [28] [29] [30] HCAECs were then rinsed with serum-free DMEM, pyruvate, glutamine, non-essential amino acids and glucose, containing NaHCO 3 (3.7 g/L) and HEPES (20 mmol/L) at pH 7.4 after confluency. HCAECs were then incubated in the medium either with or without antimycin A for 0.5-4 hours. In previous studies, the optimal exposure time and the suitable concentration of antimycm A were suggested. [28] [29] [30] For our experiments, cells were pre-incubated with inhibitors and reagents for 30 minutes, washed and exposed to antimycin A for different hour.
| HBO treatment
The oxygen tension and atmosphere absolute (ATA) for HBO were used based on previous treatment protocol 26 and our previous study. 27, 31 HCAECs were exposed to 2.5 ATA of oxygen (98% O 2 and 2% CO 2 ) in a temperature-controlled (37°C) hyperbaric chamber for 2-4 hours. ( Figure S1 ).
| Antibodies, inhibitors and reagents
Different signal pathways, including JNK, p38 mitogen-activated protein kinase (MAPK), extracellular-signal-regulated kinase (ERK) and phosphatidylinositol-3 kinase (PI-3K), in regulating hypoxia-related visfatin expression were detected by pre-treatment of HCAECs with SP600125 (20 mmol/L; a JNK pathway inhibitor), SB203580 (3 μmol/L; a p38 MAPK inhibitor), PD98059 (50 μmol/L; an ERK inhibitor) or wortmannin (50 nmol/L; a PI-3K inhibitor) 30 min, respectively, before hypoxia. All of above inhibitors were purchased from CALBIOCHEM ® . Polyclonal antibodies against visfatin were purchased from AdipoGen. Mouse monoclonal antibody against phospho-JNK was purchased from Santa Cruz Biotechnology.
Rabbit polyclonal antibodies against JNK were purchased from Cell Signaling Technology. AngII was obtained from Bachem AG. AngII type 1 receptor blocker (ARB; 100 nmol/L) was obtained from Merck & Co., Inc. N-Acetyl cysteine (NAC; a reactive oxygen species [ROS] inhibitor) was purchased from CALBIOCHEM ® . Interleukin-6 (IL-6) and TNF-α were purchased from PeproTech. L-NAME (L-arginine methyl ester; an inhibitor of nitric oxide [NO] synthase) was purchased from Merck Millpore. The working concentration of NAC, IL-6, TNF-α and L-NAME was 1 mmol/L, 10 μg/mL, 300 pg/mL and 300 μmol/L, respectively.
| Alternative method for total RNA extraction from HCAECs
Total RNA was extracted from HCAECs by using a TRI reagent. Total RNA was extracted from HCAECs using Spin Columns system by a total RNA purification kit (cat. No.217004, Qiagen) following the manufacturers' protocols. The kit is designed to facilitate lysis of tissues, to inhibit RNases and also to remove most of the cellular DNA and proteins from the lysate. Further, the total RNA quantification was assessed by measuring the ratio of spectrophotometric absorbance (260 nm/280 nm). For a pure RNA sample, this ratio should be comprised between 1.8 and 2. 
| Reverse transcription quantitative PCR
| Western blot analysis
HCAECs were homogenized in a lysis buffer (Promega Corp.) and
were then centrifuged at 10 600 g for 20 minutes at 4°C. The protein content of the supernatant was measured by using the Bio-Rad Protein Assay with BSA as the standard. The lysate was then incubated with a polyclonal anti-visfatin antibodies for 2 hours at 4°C, followed by precipitation on protein A-agarose beads. The immunoprecipitated proteins were washed three times with lysis buffer before SDS/PAGE. Western blot analysis was performed in brief as following. Equal amounts of protein (15 μg) were mixed with sample buffer, boiled for 10 minutes, separated by SDS/PAGE under denaturing conditions and electroblotted on to nitrocellulose membranes. The blots were incubated overnight in TBS (Tris-buffered saline) containing skimmed milk (5%) to block non-specific binding of the antibodies. Proteins of interest were revealed with specific antibodies at 1:1000 dilutions for 1 hour at 22°C, followed by incubation with HRP (horseradish peroxidase)-conjugated polyclonal anti-rabbit IgG antibodies (1:5000 dilution) for 1 hour at room temperature. Antibody binding was detected by using ECL ® (Amersham Biosciences). Equal protein loading of the samples was verified by staining with a mouse anti-tubulin monoclonal antibody (Sigma-Aldrich Technologies). All Western blots were finally quantified by densitometry. HCAECs were transfected with siRNA oligonucleotides, using the Effectene transfection reagent (Qiagen).
| RNA interference
| Enzyme-linked immunosorbent assay (ELISA) for AngII
The concentration of AngII was measured by a quantitative sandwich enzyme immunoassay (Phoenix Pharmaceutical, INC), with an anti-AngII antibody (Santa Cruz Biotechnology). 29 Conditioned medium from HCAECs subjected to HBO and those from control were collected for AngII measurement. The lower limit of detection of AngII was 0.5-1.5 pg/mL. Both the inter-assay and the intra-assay coefficient of variance were <10%.
| Electrophoretic mobility shift assay
Nuclear protein concentrations from cells were determined using Bio- 
| Migration assay
The migration activity of HCAECs was determined by using the method described as follows: HCAECs (5 × 10 4 cells) were seeded in each 100 mm plates for overnight. After cell have completely attached, the cells were scraped with a line in the middle of the plate by a yellow tip. The width of the line gap is around 250-280 µm. After scratching the cells, the medium was changed with fresh medium.
After incubation at 37°C for 2 hours with or without HBO, each culture was photographed at a magnification of 100× with a microscope video system. We measured the widths of three places each gap and average of them.
| Capillary-like network formation assay
Capillary-like network formation was performed in an in vitro culture system. Matrigel 250 µL (BD Biosciences) was coated onto a 24-well culture plate to solidify at 37°C for 1 hour. HCAECs on a Matrigel matrix were exposed to 2.5 ATA of oxygen in a hyperbaric chamber for 2 hours at 37°C. After HBO treatment, cells were placed in a humidified incubator for 16 hours with an atmosphere of 5% CO 2 . Capillary-like network formation was observed with a phase-contrast microscope (Nikon). 
| Statistical analysis
Data were expressed as mean ± SD. Statistical significance was performed with analysis of variance (GraphPad Software Inc). The
Tukey-Kramer comparison test was used for pairwise comparisons between multiple groups after the ANOVA. A value of P < .05 was considered to denote statistical significance.
| RE SULTS
| Hypoxia increases visfatin expression in HCAECs
HCAECs were exposed to chemical hypoxia for different periods of time (0.5, 1, 2 and 4 hours; Figure 1 , n = 4). Visfatin protein expression increased after 0.5 hour of hypoxia (1.60 ± 0.5-fold compared to control) and reached its maximal level after 2 hours (2.50 ± 0.22fold; Figure 1A,B ). Under hypoxia, visfatin mRNA expression increased after 0.5 hour (3.00 ± 0.44-fold) and reached its maximal level after 1 hour (3.26 ± 0.33-fold; Figure 1C ).
| HBO promotes earlier and greater vistafin expression in hypoxic HCACEs
To investigate the effect of HBO on visfatin expression in hypoxic HCAECs, HBO treatment was applied for 2-4 hours Figure 1C ).
| Increased visfatin protein expression in hypoxic HCAECs is mediated by the JNK pathway
As shown in Figure 2A 
| Hypoxia-and HBO-induced visfatin protein expression in HCAECs is mediated by AngII
As shown in Figure 3A 
| HBO increases HIF1α-binding to the visfatin promoter and visfatin transcription in hypoxic HCAECs
Hypoxia significantly increased the DNA-protein binding activity of HIF-1α to the visfatin promoter ( Figure 4A 
| HBO with hypoxia increases visfatin expression in the nucleus, capillary-like network formation and cell migration of HCAECs
As shown in Figure 5A (n = 4) , confocal microscopy showed visfatin expression in the nucleus after hypoxia with HBO and exogenous addition of AngII. Visfatin siRNA and losartan inhibited nucleus expression of visfatin after hypoxia with HBO. Tube formation and numbers of branching points of HCAECs also increased after hypoxia with HBO and AngII (Figure 5B,C) . Pre-treatment with SP600125, losartan or visfatin siRNA significantly blocked hypoxia and HBO-induced tube formation in HCAECs ( Figure 5B ,C, n = 4).
Cell migration assay also showed increased migration of HCAECS under hypoxia with HBO or exogenous addition of AngII. Visfatin siRNA, SP600125 and losartan also inhibited cell migration after treatment with hypoxia and HBO ( Figure 5D , n = 4).
| Recombinant visfatin and HBO increase glucose uptake in hypoxic HCAECs
Hypoxia, hypoxia with HBO and AngII significantly increased glucose uptake at various periods of incubation when compared with untreated HCAECs (Figure S2, n = 4 ). This increase in glucose uptake was attenuated by addition of visfatin siRNA, SP600125 or losartan before hypoxia.
| D ISCUSS I ON
In this study, we demonstrated several significant findings about In our study, both the JNK pathway and HIF-1α are responsible for hypoxia-induced visfatin expression modulated by HBO in HCAECs.
The vascular effects of visfatin include angiogenesis and endothelial regulation. However, different pathways of visfatin-related angiogenesis were reported in previous studies. 20, 32 In atherosclerotic plaques, visfatin stimulates MCP-1, leading to angiogenesis through NF-KB. 20, 32 Chronic treatment with visfatin has been reported to induce angiogenesis in ECs both in vivo and in vivo, providing neovascularization of atherosclerotic plaques. 9 Another mechanism by which visfatin has been shown to promote angiogenesis is through increasing NO production in human ECs, via Src, ERK1/2 and PI3K-Akt pathways. 13 However, our study showed that L-NAME did not effectively inhibit hypoxia-induced visfatin expression, suggesting that NO was not involved in hypoxia-induced visfatin expression in HCAECs in our study. ECs. 35 Our previous study also demonstrated that HBO-induced visfatin expression in HCAECs is mediated by TNF-α through the JNK pathway. 27 We tested for HCAEC stimulation in response to three pro-inflammatory cytokines and found that AngII, rather than IL NF-κB signalling. [33] [34] [35] [36] Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is the major source of visfatin-induced ROS generation in human ECs. 37 Xia et al 35 reported a mechanism for visfatin-induced endothelial regulation in coronary artery ECs, through lysosome-dependent lipid-raft signalling and activation of NADPH oxidase, leading to ROS production. However, our study showed that NAC did not effectively inhibit visfatin expression under hypoxia, suggesting that ROS production was not related to visfatin expression in hypoxic HCAECs in our study.
Our study confirmed the stimulation of angiogenesis in hypoxic HCAECs after HBO treatment through HIF-1α-related visfatin expression. Our study also demonstrated that AngII secretion increased in hypoxic HCAECs and was modulated by HBO. SP600125 and ARB attenuated the HBO-induced increase in visfatin expression. HIF-1α is a principal transcriptional factor activated by AngII and is also considered one of the downstream targets of JNK. In this study, we demonstrated that HBO increased HIF-1α binding activity. ARB and SP600125 inhibited the HIF-1α binding activity induced by hypoxia, indicating that AngII and the JNK pathway mediate the transcriptional activity of HIF-1α.
Furthermore, ARB and SP600125 attenuated the HBO-induced increase in visfatin promoter activity in hypoxic HCAECs. Our data also indicated that the HIF-1α binding site in the visfatin promoter is essential for transcriptional regulation by HBO. Thus, HIF-1α may regulate hypoxia-activated genes and play a pivotal role in cardiac protection. 36 HBO may induce expression of different genes via its unique signal pathway, depending on cell type. 24, 25 The use of hyperbaric oxygen pressure makes HBO a useful tool for the treatment of different diseases. In this study, HBO induced tube formation of hypoxic HCAECs, an essential part of angiogenesis, indicating that HBO may be beneficial for patients with refractory ischaemic cardiovascular diseases. In the present study, we found that HBO treatment stimulated migration, proliferation and angiogenesis in HCAECs. Visfatin siRNA attenuated the migration and proliferation of HCAECs induced by HBO. We found no significant cytotoxicity in response to hypoxia in HCAECs as compared to control cells ( Figure   S3 ). Visfatin has been demonstrated to improve insulin sensitivity. 3 In this study, we demonstrated that HBO increases glucose uptake in hypoxic HCAECs, as previous reported effect of visfatin. Visfatin siRNA attenuated this HBO-induced glucose uptake. This finding indicates that visfatin mediates glucose uptake by HBO in hypoxic HCAECs ( Figure S2 ). Increased glucose uptake in response to HBO may improve energy metabolism in HCAECs.
In conclusion, our study reported for the first time that both hypoxic HCAECs and exogenously added AngII increase visfatin expression. HBO enhances visfatin expression and AngII secretion and increases migration and tube formation of hypoxic HCAECs. The HBO-induced visfatin expression is mediated by AngII, mainly via the JNK pathway.
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